NASDAQ:VNDA - Vanda Pharmaceuticals Stock Price, Price Target & More

Vanda Pharmaceuticals trades on the NASDAQ under the ticker symbol "VNDA."

Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) posted its quarterly earnings data on Wednesday, February, 14th. The biopharmaceutical company reported ($0.04) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.08. The biopharmaceutical company had revenue of $44.28 million for the quarter, compared to the consensus estimate of $44 million. Vanda Pharmaceuticals had a negative return on equity of 11.94% and a negative net margin of 9.43%. Vanda Pharmaceuticals's revenue for the quarter was up 15.8% on a year-over-year basis. During the same quarter in the prior year, the business earned $0.08 earnings per share. View Vanda Pharmaceuticals' Earnings History.

Vanda Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Wednesday, May, 2nd 2018. View Earnings Estimates for Vanda Pharmaceuticals.

5 brokers have issued 1-year price targets for Vanda Pharmaceuticals' shares. Their predictions range from $18.00 to $27.00. On average, they expect Vanda Pharmaceuticals' stock price to reach $22.40 in the next twelve months. View Analyst Ratings for Vanda Pharmaceuticals.

Vanda Pharmaceuticals saw a decline in short interest during the month of March. As of March 29th, there was short interest totalling 2,380,973 shares, a decline of 29.3% from the March 15th total of 3,367,547 shares. Based on an average daily trading volume, of 1,242,810 shares, the short-interest ratio is currently 1.9 days. Currently, 4.9% of the shares of the stock are sold short.

Some companies that are related to Vanda Pharmaceuticals include Impax Laboratories (IPXL), Pacira Pharmaceuticals (PCRX), Zogenix (ZGNX), Prothena (PRTA), ImmunoGen (IMGN), Immuron (IMRN), Myovant Sciences (MYOV), G1 Therapeutics (GTHX), TherapeuticsMD (TXMD), Apellis Pharmaceuticals (APLS), Endo International (ENDP), WAVE Life Sciences (WVE), Theravance Biopharma (TBPH), PTC Therapeutics (PTCT), Mallinckrodt (MNK), Revance Therapeutics (RVNC), Dynavax Technologies (DVAX) and Epizyme (EPZM).

Headlines about VNDA stock have trended somewhat positive this week, according to Accern Sentiment. Accern identifies negative and positive press coverage by analyzing more than twenty million blog and news sources in real-time. Accern ranks coverage of companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Vanda Pharmaceuticals earned a media sentiment score of 0.11 on Accern's scale. They also assigned press coverage about the biopharmaceutical company an impact score of 46.18 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company's share price in the near future.

Shares of VNDA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

One share of VNDA stock can currently be purchased for approximately $14.85.

Vanda Pharmaceuticals has a market capitalization of $749 million and generates $165.08 million in revenue each year. The biopharmaceutical company earns $-15,560,000.00 in net income (profit) each year or ($0.35) on an earnings per share basis. Vanda Pharmaceuticals employs 273 workers across the globe.

Vanda Pharmaceuticals' mailing address is 2200 PENNSYLVANIA AVE NW SUITE 300E, WASHINGTON DC, 20037. The biopharmaceutical company can be reached via phone at 202-734-3400 or via email at [email protected]